{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:45:35Z","timestamp":1777934735027,"version":"3.51.4"},"reference-count":26,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Reuse of antineoplastic and supportive drugs can reduce costs by cutting down the amount of chemotherapy drug waste generated. Therefore, this study aims to analyze the disposal and reuse of preparations which contain these two pharmaceutical classes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a prospective study conducted with pediatric and adult patients who did not undergo one or more chemotherapy session between July and November of 2024. The chemotherapy preparations were classified as reused or discarded and quantified. The reasons for drug disposal and patient's sociodemographic data were also analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>One hundred and forty patients composed the studied population, all of them responsible for 188 missed chemotherapy sessions. The study's population is predominately adult, male, residing at Rio de Janeiro city and with less than 12 years of education. Almost half of the population (47.9%) had one or more comorbidity. The most prevalent tumors were those of the digestive system (40.1%). The drug disposal rate was 2.11%. The chemotherapy suspension rate was higher (66.3%) than non-attendance (32.6%). The patient's worsening clinical condition was the main reason (45.2%) that led to chemotherapy suspension, while miscommunication (37.1%) was the main reason attributed to non-attendance. Oxaliplatin was the most discarded drug whereas vincristine was the most reused drug.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Rate of chemotherapeutic drug disposal is higher than their reuse. Although session suspension and non-attendance are caused by different reasons, both can be reduced by implementation of an effective communication routine between patient and provider in the days prior to the scheduled session.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552261418212","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T18:10:41Z","timestamp":1769796641000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Analysis of disposal and reuse of antineoplastic and supportive drugs in an oncology reference institution"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-0268-7485","authenticated-orcid":false,"given":"Suely de Menezes","family":"Ribeiro","sequence":"first","affiliation":[{"name":"National Cancer Institute (INCA)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9648-0891","authenticated-orcid":false,"given":"Erika da Silva","family":"Magliano","sequence":"additional","affiliation":[{"name":"National Cancer Institute (INCA)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5672-8602","authenticated-orcid":false,"given":"Elizangela Domiciano Garcia","family":"Barreto","sequence":"additional","affiliation":[{"name":"National Cancer Institute (INCA)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0883-562X","authenticated-orcid":false,"given":"Filipe dos Santos","family":"Soares","sequence":"additional","affiliation":[{"name":"National Cancer Institute (INCA)"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"key":"e_1_3_2_2_2","first-page":"60","volume-title":"Instituto Nacional de C\u00e2ncer Jos\u00e9 Alencar Gomes da Silva \u2013 INCA. Gloss\u00e1rio tem\u00e1tico: Controle de c\u00e2ncer","author":"Minist\u00e9rio da Sa\u00fade (BRASIL)","year":"2013","unstructured":"Minist\u00e9rio da Sa\u00fade (BRASIL). Instituto Nacional de C\u00e2ncer Jos\u00e9 Alencar Gomes da Silva \u2013 INCA. Gloss\u00e1rio tem\u00e1tico: Controle de c\u00e2ncer. Bras\u00edlia: Minist\u00e9rio da Sa\u00fade, 2013, p.60."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834"},{"key":"e_1_3_2_4_2","volume-title":"Ambiente, trabalho e c\u00e2ncer: aspectos epidemiol\u00f3gicos, toxicol\u00f3gicos e regulat\u00f3rios","author":"Instituto Nacional de C\u00e2ncer Jos\u00e9 Alencar Gomes da Silva (INCA)","year":"2021","unstructured":"Instituto Nacional de C\u00e2ncer Jos\u00e9 Alencar Gomes da Silva (INCA). Ambiente, trabalho e c\u00e2ncer: aspectos epidemiol\u00f3gicos, toxicol\u00f3gicos e regulat\u00f3rios. Rio de Janeiro: INCA, 2021."},{"key":"e_1_3_2_5_2","volume-title":"Estimativa 2023: incid\u00eancia de c\u00e2ncer no Brasil","author":"Instituto Nacional de C\u00e2ncer Jos\u00e9 Alencar Gomes da Silva (INCA)","year":"2023","unstructured":"Instituto Nacional de C\u00e2ncer Jos\u00e9 Alencar Gomes da Silva (INCA). Estimativa 2023: incid\u00eancia de c\u00e2ncer no Brasil. Rio de Janeiro: INCA, 2023."},{"key":"e_1_3_2_6_2","first-page":"7530794","article-title":"Radiotherapy\/chemotherapy-immunotherapy for cancer management: from mechanisms to clinical implications","volume":"2023","author":"Li Q","unstructured":"Li Q, Lei X, Zhu J, et al. Radiotherapy\/chemotherapy-immunotherapy for cancer management: from mechanisms to clinical implications. Oxid Med Cell Longev 2023 Feb 2; 2023: 7530794.","journal-title":"Oxid Med Cell Longev"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.2174\/1566523221666211119110755"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.17696\/2318-3691.22.3.2015.107"},{"key":"e_1_3_2_9_2","volume-title":"Toxicidade ao Tratamento Quimioter\u00e1pico em Mulheres com C\u00e2ncer de Mama. [Tese de Doutorado]","author":"Gozzo TO","year":"2008","unstructured":"Gozzo TO. Toxicidade ao Tratamento Quimioter\u00e1pico em Mulheres com C\u00e2ncer de Mama. [Tese de Doutorado]. Ribeir\u00e3o Preto (SP): Escola de Enfermagem de Ribeir\u00e3o Preto\/USP, 2008. f.113."},{"key":"e_1_3_2_10_2","first-page":"237","volume-title":"Oncologia b\u00e1sica","author":"Crisanto MLLP","year":"2012","unstructured":"Crisanto MLLP. Princ\u00edpios de quimioterapia. In: Vieira SC (eds) Oncologia b\u00e1sica. 1\u00aa ed. Teresina, PI: Funda\u00e7\u00e3o Quixote, 2012, pp.237\u2013252.","edition":"1"},{"key":"e_1_3_2_11_2","first-page":"3","volume-title":"Terap\u00eautica oncol\u00f3gica para enfermeiros e farmac\u00eauticos","author":"Bonassa EMA","year":"2005","unstructured":"Bonassa EMA, Gato MIR. Conceitos gerais em quimioterapia antineopl\u00e1sica. In: Bonassa EMA, Gato MIR (eds) Terap\u00eautica oncol\u00f3gica para enfermeiros e farmac\u00eauticos. 4\u00aa ed. S\u00e3o Paulo: Atheneu, 2005, pp.3\u201319.","edition":"4"},{"key":"e_1_3_2_12_2","first-page":"44","volume-title":"O desperd\u00edcio de quimioterapia no tratamento do c\u00e2ncer e estrat\u00e9gias para redu\u00e7\u00e3o do seu impacto social, ambiental e econ\u00f4mico: uma an\u00e1lise preliminar. [Trabalho de Conclus\u00e3o de Curso]","author":"Hyeda A","year":"2014","unstructured":"Hyeda A. O desperd\u00edcio de quimioterapia no tratamento do c\u00e2ncer e estrat\u00e9gias para redu\u00e7\u00e3o do seu impacto social, ambiental e econ\u00f4mico: uma an\u00e1lise preliminar. [Trabalho de Conclus\u00e3o de Curso]. Curitiba: ISAE\/FGV, Programa FGV Management, 2014, p.44."},{"key":"e_1_3_2_13_2","first-page":"84","article-title":"Resolu\u00e7\u00e3o n\u00b0 623, de 29 de abril de 2016 (alterada pela Resolu\u00e7\u00e3o n\u00b0 640, de 27 de abril de 2017)","volume":"83","author":"Conselho Federal de Farm\u00e1cia","unstructured":"Conselho Federal de Farm\u00e1cia. Resolu\u00e7\u00e3o n\u00b0 623, de 29 de abril de 2016 (alterada pela Resolu\u00e7\u00e3o n\u00b0 640, de 27 de abril de 2017). Di\u00e1rio Oficial da Rep\u00fablica Federativa do Brasil, Bras\u00edlia, DF 2016 maio 3; 83: 84.","journal-title":"Di\u00e1rio Oficial da Rep\u00fablica Federativa do Brasil, Bras\u00edlia, DF"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vhri.2015.08.001"},{"key":"e_1_3_2_15_2","volume-title":"An\u00e1lise farmacoecon\u00f4mica do reaproveitamento de medicamentos antineopl\u00e1sicos injet\u00e1veis reconstitu\u00eddos. 49 f. Monografia (Resid\u00eancia em Farm\u00e1cia Hospitalar)","author":"Silveira ACFBd","year":"2017","unstructured":"Silveira ACFBd. An\u00e1lise farmacoecon\u00f4mica do reaproveitamento de medicamentos antineopl\u00e1sicos injet\u00e1veis reconstitu\u00eddos. 49 f. Monografia (Resid\u00eancia em Farm\u00e1cia Hospitalar). Niter\u00f3i, Rio de Janeiro, Brazil: Universidade Federal Fluminense, 2017."},{"key":"e_1_3_2_16_2","first-page":"765","article-title":"The cost of cancer treatment in Portugal","volume":"11","author":"Lopes JM","unstructured":"Lopes JM, Gon\u00e7alves FR, Borges M, et al. The cost of cancer treatment in Portugal. Ecancermedicalscience 2017 Sep 6; 11: 765.","journal-title":"Ecancermedicalscience"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2011.000318"},{"key":"e_1_3_2_18_2","first-page":"277","article-title":"Gest\u00e3o de custos e res\u00edduos na utiliza\u00e7\u00e3o de quimioter\u00e1picos antineopl\u00e1sicos","volume":"9","author":"Silva BQ","year":"2017","unstructured":"Silva BQ, Trombini MM, Silva JAC. Gest\u00e3o de custos e res\u00edduos na utiliza\u00e7\u00e3o de quimioter\u00e1picos antineopl\u00e1sicos. Jornal Bras Econ Sa\u00fade 2017; 9: 277\u2013281.","journal-title":"Jornal Bras Econ Sa\u00fade"},{"key":"e_1_3_2_19_2","first-page":"54","article-title":"Acessibilidade e utiliza\u00e7\u00e3o na aten\u00e7\u00e3o b\u00e1sica: reflex\u00f5es sobre o absente\u00edsmo dos usu\u00e1rios","volume":"18","author":"Trist\u00e3o FI","year":"2016","unstructured":"Trist\u00e3o FI, Lima R de CD, Lima EdF, et al. Acessibilidade e utiliza\u00e7\u00e3o na aten\u00e7\u00e3o b\u00e1sica: reflex\u00f5es sobre o absente\u00edsmo dos usu\u00e1rios. Rev Bras Pesq Sa\u00fade 2016; 18: 54\u201361.","journal-title":"Rev Bras Pesq Sa\u00fade"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1590\/S0102-311X2010000400015"},{"key":"e_1_3_2_21_2","volume-title":"Desigualdades sociais por cor ou ra\u00e7a no Brasil","author":"Instituto Brasileiro de Geografia e Estat\u00edstica (IBGE)","year":"2022","unstructured":"Instituto Brasileiro de Geografia e Estat\u00edstica (IBGE). Desigualdades sociais por cor ou ra\u00e7a no Brasil. 2\u00aa ed. Rio de Janeiro: IBGE, 2022. (Estudos e Pesquisas. Informa\u00e7\u00e3o Demogr\u00e1fica e Socioecon\u00f4mica, n. 48).","edition":"2"},{"key":"e_1_3_2_22_2","volume-title":"Pol\u00edtica Nacional de Sa\u00fade Integral da Popula\u00e7\u00e3o Negra","author":"Minist\u00e9rio da Sa\u00fade (BRASIL)","year":"2017","unstructured":"Minist\u00e9rio da Sa\u00fade (BRASIL). Pol\u00edtica Nacional de Sa\u00fade Integral da Popula\u00e7\u00e3o Negra. Bras\u00edlia: Minist\u00e9rio da Sa\u00fade, 2017."},{"key":"e_1_3_2_23_2","volume-title":"S\u00edntese de indicadores sociais: uma an\u00e1lise das condi\u00e7\u00f5es de vida da popula\u00e7\u00e3o brasileira","author":"Instituto Brasileiro de Geografia e Estat\u00edstica (IBGE)","year":"2016","unstructured":"Instituto Brasileiro de Geografia e Estat\u00edstica (IBGE). S\u00edntese de indicadores sociais: uma an\u00e1lise das condi\u00e7\u00f5es de vida da popula\u00e7\u00e3o brasileira. Rio de Janeiro: IBGE, 2016."},{"key":"e_1_3_2_24_2","first-page":"113","volume-title":"Pesquisa Nacional de Sa\u00fade: 2019: percep\u00e7\u00e3o do estado de sa\u00fade, estilos de vida, doen\u00e7as cr\u00f4nicas e sa\u00fade bucal: Brasil e grandes regi\u00f5es","author":"Instituto Brasileiro de Geografia e Estat\u00edstica (IBGE)","year":"2020","unstructured":"Instituto Brasileiro de Geografia e Estat\u00edstica (IBGE). Pesquisa Nacional de Sa\u00fade: 2019: percep\u00e7\u00e3o do estado de sa\u00fade, estilos de vida, doen\u00e7as cr\u00f4nicas e sa\u00fade bucal: Brasil e grandes regi\u00f5es. Rio de Janeiro: IBGE, 2020, p.113."},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1177\/10781552241264288"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1590\/1518-8345.3258.3275"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-14-57"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261418212","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552261418212","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261418212","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:32:17Z","timestamp":1777689137000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552261418212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":26,"alternative-id":["10.1177\/10781552261418212"],"URL":"https:\/\/doi.org\/10.1177\/10781552261418212","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]},"article-number":"10781552261418212"}}